NovoCure Limited Ordinary Shares

Day range

$14.39 – $14.90

Open

$14.47

Prev close

$14.68

Volume

379.69K

Market cap

$1.71B

Shares out

116.45M

P/E

—

P/S

2.44

P/B

5.06

P/FCF

—

ROE

-43.9%

ROA

-18.7%

Debt/Equity

0.58

Div yield

0.00%

As of Oct 23, 2026

• Regulatory decisionOct 1, 2026

  On September 15, 2026, the Company issued a press release announcing that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.

• Director departureSep 9, 2026

  Timothy Scannell, a current director of NovoCure Limited (the "Company"), has retired from the Board and his seat was formally vacated pursuant to the Company's Articles of Association effective September 2, 2026. Mr. Scannell's retirement from the Board after five years of distinguished service did not result from any disagreement with the Company or its management.

• Cybersecurity incidentSep 1, 2026

  In mid-August 2026, NovoCure Limited (the "Company," "we," or "us") through a subsidiary, became aware of unauthorized access to some of its information systems. Upon detecting the unauthorized access, the Company activated its cybersecurity response plan, implemented containment measures, and initiated an internal investigation of the event.

• Clinical trial resultsJun 18, 2026

  The trial did not demonstrate a statistically significant improvement in the primary endpoint of overall survival for the Early Start Arm compared to the Maintenance Start Arm. In the intent-to-treat (ITT) population, the Early Start Arm had a median overall survival of 17.7 months compared to 17.5 months in Maintenance Start Arm (HR 0.953; p=0.519).

• Annual meeting resultsJun 5, 2026

  At the Annual Meeting, proxies and in-person shareholders representing 93,826,730 shares of the Company's ordinary shares, or approximately 81.01% of the total shares entitled to vote, were present in person or by proxy and voted on the following proposals... The eleven nominees for election to the Company's Board of Directors were elected as directors to hold office until the Company's 2027 Annual Meeting of Shareholders.

Days to cover

10.1

Short interest

11.16M

Avg volume

1.11M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Novocure Reports Patient Data Exposure in Cybersecurity Incident
  neutralZacks Investment Research· Sep 7, 2026
• Stock Market Today, June 4: Broadcom Drags on Nasdaq at Midday
  negativeThe Motley Fool· Jun 4, 2026
• Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight
  positiveGlobeNewswire Inc.· May 27, 2026
• New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
  positiveBenzinga· Feb 17, 2026
• Soleus Adds a Significant Number of Celcuity Shares
  positiveThe Motley Fool· Feb 13, 2026